Z Ming1, R Parent, M Lavallée. 1. Department of Physiology, Faculty of Medicine, Université de Montréal, Québec, Canada.
Abstract
BACKGROUND: We considered that beta 2-adrenergic stimulation may dilate resistance coronary vessels by opening ATP-sensitive potassium (KATP) channels, thereby triggering NO formation. METHODS AND RESULTS: In conscious instrumented dogs after beta 1-adrenergic blockade, intracoronary (IC) injections of acetylcholine (ACh), nitroglycerin (NTG), and pirbuterol (PIR), a selective beta 2-adrenergic agonist, were performed before and after blockade of NO formation with IC N omega-nitro-L-arginine methyl ester (L-NAME, 50 micrograms.kg-1.min-1 x 12 minutes) or blockade of KATP channels with IC glibenclamide (25 micrograms.kg-1.min-1 x 12 minutes followed by 2 micrograms.kg-1.min-1). PIR (50.0 ng/kg) increased coronary blood flow (CBF) by 32 +/- 6 from 43 +/- 7 mL/min and by only 11 +/- 2 (P < .01) from 40 +/- 7 mL/min after L-NAME. Increases in CBF to ACh were also reduced by L-NAME, but NTG responses were not. Before glibenclamide, PIR increased CBF by 33 +/- 5 from 45 +/- 7 mL/min and by only 14 +/- 3 (P < .01) from 36 +/- 5 mL/min thereafter. CBF responses to ACh and NTG were maintained after glibenclamide. Lemakalim, a selective opener of KATP channels, caused dose-dependent increases in CBF that were partially inhibited by L-NAME. In experiments in which CBF was controlled, the fall in distal coronary pressure caused by PIR was less after L-NAME or glibenclamide than before. CONCLUSIONS: beta 2-Adrenergic dilation of resistance coronary vessels involves both the opening of KATP channels and NO formation. L-NAME antagonized lemakalim responses consistent with a link between the opening of KATP channels and NO formation in canine resistance coronary vessels.
BACKGROUND: We considered that beta 2-adrenergic stimulation may dilate resistance coronary vessels by opening ATP-sensitive potassium (KATP) channels, thereby triggering NO formation. METHODS AND RESULTS: In conscious instrumented dogs after beta 1-adrenergic blockade, intracoronary (IC) injections of acetylcholine (ACh), nitroglycerin (NTG), and pirbuterol (PIR), a selective beta 2-adrenergic agonist, were performed before and after blockade of NO formation with IC N omega-nitro-L-arginine methyl ester (L-NAME, 50 micrograms.kg-1.min-1 x 12 minutes) or blockade of KATP channels with IC glibenclamide (25 micrograms.kg-1.min-1 x 12 minutes followed by 2 micrograms.kg-1.min-1). PIR (50.0 ng/kg) increased coronary blood flow (CBF) by 32 +/- 6 from 43 +/- 7 mL/min and by only 11 +/- 2 (P < .01) from 40 +/- 7 mL/min after L-NAME. Increases in CBF to ACh were also reduced by L-NAME, but NTG responses were not. Before glibenclamide, PIR increased CBF by 33 +/- 5 from 45 +/- 7 mL/min and by only 14 +/- 3 (P < .01) from 36 +/- 5 mL/min thereafter. CBF responses to ACh and NTG were maintained after glibenclamide. Lemakalim, a selective opener of KATP channels, caused dose-dependent increases in CBF that were partially inhibited by L-NAME. In experiments in which CBF was controlled, the fall in distal coronary pressure caused by PIR was less after L-NAME or glibenclamide than before. CONCLUSIONS: beta 2-Adrenergic dilation of resistance coronary vessels involves both the opening of KATP channels and NO formation. L-NAME antagonized lemakalim responses consistent with a link between the opening of KATP channels and NO formation in canine resistance coronary vessels.